Triple
T10292128
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | bortezomib |
E241388
|
entity |
| Predicate | hasTradeName |
P24555
|
FINISHED |
| Object | Bortezomib Accord |
E241388
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Bortezomib Accord | Statement: [bortezomib, hasTradeName, Bortezomib Accord]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Bortezomib Accord Context triple: [bortezomib, hasTradeName, Bortezomib Accord]
-
A.
bortezomib
chosen
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
B.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
C.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
D.
Tasigna
Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
-
E.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381aaafc08190af475ef58dc16aba |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d4d2d35f048190a215493acdf1f718 |
completed | April 7, 2026, 9:48 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d6f85dcbac8190a2ac66354010e328 |
completed | April 9, 2026, 12:52 a.m. |
Created at: April 6, 2026, 11:42 a.m.